A detailed history of Qtron Investments LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Qtron Investments LLC holds 3,131 shares of VRTX stock, worth $1.28 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
3,131
Previous 4,731 33.82%
Holding current value
$1.28 Million
Previous $2.22 Million 34.33%
% of portfolio
0.2%
Previous 0.33%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $736,000 - $809,248
-1,600 Reduced 33.82%
3,131 $1.46 Million
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $393,988 - $486,986
1,003 Added 26.9%
4,731 $2.22 Million
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $29,761 - $32,563
-73 Reduced 1.92%
3,728 $1.56 Million
Q4 2023

Feb 12, 2024

SELL
$343.0 - $410.68 $75,460 - $90,349
-220 Reduced 5.47%
3,801 $1.55 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $191,409 - $205,152
566 Added 16.38%
4,021 $1.4 Million
Q1 2023

May 11, 2023

SELL
$283.23 - $323.1 $87,801 - $100,161
-310 Reduced 8.23%
3,455 $1.09 Million
Q1 2022

May 05, 2022

BUY
$221.42 - $260.97 $833,646 - $982,552
3,765 New
3,765 $983,000
Q2 2021

Aug 11, 2021

SELL
$187.49 - $221.1 $174,928 - $206,286
-933 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $350,277 - $408,296
-1,692 Reduced 64.46%
933 $200,000
Q3 2020

Nov 12, 2020

SELL
$255.65 - $303.1 $52,919 - $62,741
-207 Reduced 7.31%
2,625 $714,000
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $130,552 - $171,268
579 Added 25.7%
2,832 $822,000
Q1 2020

May 14, 2020

BUY
$199.77 - $247.81 $450,081 - $558,315
2,253 New
2,253 $536,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Qtron Investments LLC Portfolio

Follow Qtron Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qtron Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Qtron Investments LLC with notifications on news.